key: cord-0875146-7fd4fcah
authors: Ghiasi, Maryam; Nasimi, Maryam; Ghandi, Narges; Lajevardi, Vahideh; Abedini, Robabeh; Azizpour, Arghavan; Ansari, Mahshid Sadat; kheiltash, Azita; Balighi, Kamran
title: COVID‐19 infection risk in patients on immunosuppressive/immunomodulator therapy: A single center study
date: 2021-09-19
journal: Dermatol Ther
DOI: 10.1111/dth.15126
sha: 1d247a60c865790717eb5b6824c079f4e2b17cf3
doc_id: 875146
cord_uid: 7fd4fcah

nan

Dear editor, Many dermatologic conditions need immunosuppressive therapy and following the outbreak of COVID-19 there were concerns about susceptibility of patients to infection or undesirable outcome. 1, 2 In this cross-sectional study, we report the incidence of COVID positive PCR test were symptomatic. Most common symptoms were fever (55%), shiver (50%), body pain (50%), and cough (35%). In patients receiving immunosuppressive/immunomodulatory drugs symptoms such as fever, shiver, cough, body pain, nausea, vomiting, diarrhea, and dyspnea were significantly more than those on nonimmunosuppressive therapy (p value <0.05). Exposure history was positive in seven patients. Only one patient was admitted who was on methotrexate for dermatitis and suffer from cardiovascular disorders.

Mortality was not observed. Among patients with psoriasis and LPP, COVID-19 was diagnosed in 13 and 4 of them, respectively; and no significant relationship was found between COVID-19 infection and immunosuppressive/immunomodulatory therapy in these patients (p value = 0.59 and 0.24, respectively). In COVID-19 infected psoriatic patients there was also no significant difference between treatment with adalimumab and other immunosuppressive drugs (p value = 0.75).

We did not find any significant relationship between co-morbidities 

Combination therapy (17) 1 12

Total ( (2), Haily-Haily disease (2), hidradenitis suppurativa (2), prurigo nodularis (1), graftversus-host disease (1), erosive lichen planus (2) . b None of patients receiving hydroxychloroquine was infected.

Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study

Navigating immunosuppression in a pandemic: a guide for the dermatologist from the COVID task force of the medical dermatology society and Society of Dermatology Hospitalists

Patients with specific skin disorders who are affected by COVID-19: what do experiences say about management strategies? A systematic review

Managing cutaneous immune-mediated diseases during the COVID-19 pandemic

COVID-19 and immunomodulator/immunosuppressant use in dermatology

Cytokine storm and probable role of immunoregulatory drugs in COVID-19: a comprehensive review

COVID-19 and biologic therapies in dermatology: seroprevalence survey and severity analysis in a tertiary hospital in Spain

Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: a multicenter research network study

Evidence following guidelines: another COVID-19 paradox

Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic

Immunosuppressive therapies for alopecia areata during COVID-19: a cross-sectional survey study